Bio
Kavita Iyer 毕业于孟买大学，获得药学学士学位。随后，她在弗吉尼亚联邦大学 (VCU) 获得了药物化学博士学位。她还在弗吉尼亚联邦大学生理学和生物物理学系从事博士后研究，接受结构生物学方面的培训，并随后担任研究科学家。在 CAS 工作期间，Kavita 涉猎广泛领域，包括免疫肿瘤学、CRISPR 疗法、罕见病、生命科学中的纳米生物传感器，以及药物化学中的共价抑制剂和 PROTACs。
新兴科学
Shifting climate, spreading insects: The rising burden of vector-borne diseases
Vector-borne diseases are spreading to new regions as climate change intensifies, and public health systems need more treatment options to limit the impacts.
Biotechnology
Could xenotransplantation solve organ transplant shortages?
With the advent of genetic editing technology, researchers are increasingly able to address immuno-compatibility issues, getting closer to making organs and tissues available for transplant from animal donors to human recipients.
药物开发
抗癌PPI抑制剂在临床试验中取得进展
小分子 PPI 抑制剂即将改善癌症治疗
新兴科学
Co-occurring concepts reveal new research directions in immuno-oncology
Concept co-occurrence analysis shows the newest ideas in scientific discovery and drives innovation in immuno-oncology.
药物开发
PROTACs revolutionize small molecule drugs
PROTACs are driving small molecule drug development to treat cancer, neurodegenerative diseases and more
Biotechnology
网络研讨会：癌症治疗探索的大数据见解
最近举行的癌症与大数据专家网络研讨会揭示了免疫肿瘤学的新兴趋势、数据挑战以及研究人员面临的机遇。
药物开发
免疫疗法和癌症的新兴趋势
在本文中揭示免疫肿瘤学出版物和研究领域的新趋势，确定未来的新机遇和挑战。